May 8th 2024
Findings from the CheckMate-901 study support the use of frontline nivolumab plus gemcitabine/cisplatin in advanced urothelial carcinoma.
Evaluating Two RT-Plus-Chemotherapy Strategies in Bladder Cancer Patients Undergoing Bladder Surgery
March 7th 2018In this interview, we spoke with John J. Coen, MD, a radiation oncologist who presented results at the 2018 Genitourinary Cancers Symposium of a phase II study exploring two different radiation-plus-chemotherapy combination strategies in patients undergoing bladder surgery for their tumors.
Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.
Pooled Analysis Shows Avelumab Promising in Advanced Urothelial Carcinoma
December 16th 2017The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer Patients
November 8th 2017In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Analysis Highlights Gaps in Cisplatin-Based Treatment for Advanced Urinary Tract Cancer
November 4th 2017An analysis of treatment patterns found that patients with advanced urinary tract cancer who are eligible for cisplatin-based chemotherapy fare better when they do receive such regimens than when they do not, highlighting the importance of following published treatment criteria.
Adding Ramucirumab Prolongs PFS in Urothelial Carcinoma
September 13th 2017The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.
Extended Results Confirm Pembrolizumab Superiority in Recurrent Urothelial Carcinoma
September 12th 2017The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.